Allan is a pharmaceutical and biotech executive with more than 25 years’ experience in research, development, licensing, and mergers and acquisitions. Allan has been instrumental in the growth of several biotechnology and pharmaceutical companies over his career. In addition to his role at Trepso, he is currently Chairman of Searchlight Pharma and a member of the Boards of Matrizyme Pharma, Kane Biotech and Exactis Innovation. Previously, Allan sat on the Boards of both Clementia Pharmaceuticals (acquired by Ipsen in 2019) and Bedrocan Cannabis Corporation (amalgamated into Canopy Growth Corporation in 2015). He served as CEO and director at Thallion Pharmaceuticals until its acquisition by Bellus Health in 2013, and as vice president of business development at Labopharm from 2000 until 2006, through its NASDAQ listing and $100 million capital raise. Before this, Allan held senior research and business development roles with Allelix Biopharmaceuticals and NPS-Allelix Corp. He has a PhD in physiology and an MBA from McGill University and holds a BSc from the University of Toronto. He received his post-doctoral training at the Roche Institute of Molecular Biology.